• Home
  • About
  • Success Stories

Name: HylaPharm

HylaPharm is a drug delivery company now producing its patented HylaPlat technology, which delivers chemotherapy drugs directly to cancer cells in tumors and nearby lymph nodes while limiting drug exposure in kidneys, nerves and auditory organs. By limiting exposure in these surrounding areas, HylaPlat enables targeted treatments with fewer side effects.

www.hylapharm.com

Name: Immunogenetix Therapeutics, Inc.

Immunogenetix Therapeutics, Inc. is an early stage biotechnology company developing advanced DNA-based therapies for the prevention and treatment of HIV infection. DNA-based therapies offer significant advantages over recombinant protein therapies, including an enhanced cellular immune response and long-term protection against viral diseases that require cellular immunity (e.g. HIV). The Company has exclusive worldwide rights to proprietary therapeutic candidates and supporting technologies.

http://immunogenetix.com

Name: ImmuPep, Inc
ImmuPep, Inc. Dedicated to modern immunotherapy. ImmuPep is a start-up biotechnology company founded to develop new approaches to modulating the immune and inflammatory responses and to treat disorders of the immune response. The principal technology inhibits, in a specific manner, the small subset of immune cells that cause autoimmune disease or rejection of organ transplants while leaving the rest of the immune system to function normally. This is in direct contrast with therapies currently on the market that inhibit the entire immune response and result in generalized immune or inflammatory suppression that lead to unwanted side effects such as sepsis. Targeted diseases include rheumatoid arthritis, multiple sclerosis, insulin-dependent diabetes, and psoriasis as well as rejection of organ transplants. Technologies under development include anti-viral agents and diagnostic immunoassays.

Name: Innara Health TM formerly KC BioMediX, Inc.

Innara Health TM formerly KC BioMediX, Inc. is a medical device company that was established to commercialize technologies developed at the University of Kansas for the care and treatment of infants born prematurely. Specifically, the company is developing medical devices based upon technologies that measure, monitor and develop the non-nutritive suck – an essential building block in an infant’s development of the coordinated sucking, breathing and swallowing capability needed for independent oral feed.

www.kcbiomedix.com

Name: KanPro Research

KanPro Research, LLC is a contract research organization (CRO) headquartered in the Bioscience & Technology Business Center at the University of Kansas. The company specializes in recombinant protein expression and purification from mammalian and cell-free systems. KanPro seeks contract research partnerships with academic and industrial researchers.  The company has special expertise in producing challenging proteins including those that have previously failed.  KanPro Research also manufactures, tests biochemical reagents, kits and equipment and provides advice and consultation services. 

Watch the "Inside KU" video featuring KanPro Research.

 

Pages


Events
KU Today